Alpine Woods Capital Investors’s iShares Biotechnology ETF IBB Stock Holding History

Alpine Woods Capital Investors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-133,200	Closed	-$14.2M	–	307
2018 Q1	$14.2M	Hold	133,200	–	–	0.75%	44
2017 Q4	$14.2M	Buy	+133,200	New	+$14.2M	0.71%	43

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Alpine Woods Capital Investors's IBB Position: Q2 2018 in Review

Alpine Woods Capital Investors sold out of iShares Biotechnology ETF (IBB) in Q2 2018, closing a stake of 133,200 shares — an estimated $14.2M sold.

Alpine Woods Capital Investors first reported a position in IBB in Q4 2017 and held it in 2 quarters. The position peaked at $14.2M in Q4 2017. 608 funds tracked by Wall St. Rank hold IBB as of Q2 2018.

Alpine Woods Capital Investors reported no remaining iShares Biotechnology ETF position as of Q2 2018 after selling out during the quarter.
Alpine Woods Capital Investors sold 133,200 iShares Biotechnology ETF shares in Q2 2018, an estimated $14.2M.
Alpine Woods Capital Investors first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 2 quarters.
Alpine Woods Capital Investors's iShares Biotechnology ETF position peaked at $14.2M in Q4 2017.
608 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2018.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2018, filed 9 Aug 2018.